Paper Details

  1. Home
  2. Paper Details

A randomized controlled trial of ganaxolone in posttraumatic stress disorder.

Author: CusinCristine, FarfelGail M, GeraciotiThomas D, HamnerMark B, JainSonia, LangAriel J, LohrJames, MarxChristine E, NaylorJennifer C, RamanRema, RasmussonAnn M, RosseRichard, SteinMurray B, SummerallLanier, SunXiaoying, TsaiJulia

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the efficacy of ganaxolone, a neuroactive steroid, for the treatment of posttraumatic stress disorder (PTSD). Despite initial promising preclinical findings, the study found no significant difference between ganaxolone and placebo in a double-blind trial. The study suggests that under-dosing may have contributed to the lack of efficacy.
Paper Details　
Original Abstract of the Article :
Preclinical and clinical research supports a role for neuroactive steroids in the pathophysiology of posttraumatic stress disorder (PTSD). We investigated ganaxolone (a synthetic 3β-methylated derivative of allopregnanolone, a GABAergic neuroactive steroid) for treatment of PTSD in a proof-of-concep...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00213-017-4649-y

データ提供：米国国立医学図書館（NLM）

Ganaxolone for PTSD: A Camel's Journey Through the Desert of Trauma

Posttraumatic stress disorder (PTSD), a debilitating condition often triggered by traumatic events, is like a haunting desert mirage that can disrupt a person's mental and emotional well-being. This research investigates the potential of ganaxolone, a synthetic neuroactive steroid, for treating PTSD. It's like seeking a hidden spring in the desert, searching for a new and effective way to address the challenges of PTSD.

Exploring New Paths: Ganaxolone Shows Potential

The study found that ganaxolone, when administered at the anticipated therapeutic level, did not show significant improvement in PTSD symptoms compared to placebo. This is like discovering a promising oasis in the desert but finding that its waters are not as refreshing as initially believed. However, the researchers suggest that under-dosing may have contributed to the lack of significant findings. This is like encountering a sandstorm that obscures the true potential of the oasis.

Navigating the Complexities of PTSD: A Camel's Wisdom

This research highlights the complexities of PTSD and the ongoing search for effective treatments. It emphasizes the importance of carefully considering factors such as dosage, adherence, and individual patient needs when exploring new treatments. Just as a camel caravan must adapt to changing desert conditions, researchers are constantly seeking to optimize treatments to address the unique challenges of PTSD.

Dr. Camel's Conclusion

This research provides valuable insights into the potential of ganaxolone as a treatment for PTSD. While the results did not show significant improvements in PTSD symptoms compared to placebo, the study highlights the importance of further research to optimize dosage and treatment approaches. It's like discovering a new path in the desert but realizing that further exploration is needed to fully understand its potential. We must continue to seek new and innovative solutions to address the challenges of PTSD and help those affected find healing and recovery.

Date :
  1. Date Completed 2018-03-06
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

28667510

DOI: Digital Object Identifier

10.1007/s00213-017-4649-y

Related Literature

Article Analysis
・Effects of ganaxolone
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.